Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)
NCT06393712 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)
- Lead sponsor
- Alnylam Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 17, 2024
- Completion date
- December 14, 2029
- Enrollment
- 210 (actual)
- Sites
- 57
Conditions
As the registry lists them; a condition with its own page is linked.